

HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 1021

PRINTER'S NO. 3053

PRIME SPONSOR: Sanchez

COST / (SAVINGS)

FUND	FY 2023/24	FY 2024/25
Insurance Regulation and Oversight Fund	\$0	\$0

SUMMARY:

This legislation prohibits insurance companies from denying, canceling or refusing to renew an application for or a current life insurance policy based solely on the fact that the applicant or enrollee obtained or filled a prescription for an opioid overdose reversal agent.

ANALYSIS:

House Bill 1021 Printer's Number 3053 prohibits insurance companies from taking an adverse action on a life insurance policy against an applicant or enrollee based solely on information that shows that applicant or enrollee obtained or filled a prescription for an opioid overdoes reversal agent.

Adverse action is defined as follows:

- Denying, cancelling, or refusing to renew insurance coverage for an applicant.
- Limiting the amount, extent or kind of insurance coverage.
- Charging an applicant or enrollee a rate that is different from the rate charged to other applicants or enrollees.

A violation of this legislation will be considered unfair discrimination under Act 284 of 1921, known as the Insurance Company Law of 1921, and unfair method of competition or unfair or deceptive acts or practices under Act 205 of 1974, known as the Unfair Insurance Practices Act.

FISCAL IMPACT:

The Department of Insurance has the responsibility to ensure that insurance companies comply with the requirements included in this legislation. Currently, the department does not anticipate an increase in administrative costs due to this legislation, which is funded through the Insurance Regulation and Oversight Fund. Therefore, there is no fiscal impact to the commonwealth.

PREPARED BY: Mara Perez, Senior Budget Analyst

House Appropriations Committee (D)

DATE: June 10, 2024

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.